Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction …
$6.72+5.41%
报价 2026-11-06
市值
$691.5M
EV
$842.7M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -21.2%
$2.65$8.53
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ACHVAchieve Life Sciences, Inc. | $691.5M | +5.4% | – | 0% | – | – | – | |
| SANASana Biotechnology, Inc. | $709.5M | +1.3% | – | 0% | – | – | – | |
| SLDBSolid Biosciences Inc. | $706.6M | +6.6% | +146.7% | 0% | – | – | – | |
| ATTOAttovia Therapeutics, Inc. | $697.1M | +1.8% | – | -8.4% | – | – | – | |
| ZVRAZevra Therapeutics, Inc. | $688.3M | +10.1% | +47.0% | 95% | 9.1x | 6.8x | 18.0x | |
| ANNXAnnexon, Inc. | $688.1M | +4.9% | -77.8% | 0% | – | – | – | |
| NVCTNuvectis Pharma, Inc. | $682.6M | +17.7% | -87.0% | 0% | – | – | – | |
| AURAAura Biosciences, Inc. | $680.3M | +3.5% | +2.7% | 0% | – | – | – | |
| FDMT4D Molecular Therapeutics, Inc. | $676.7M | +8.9% | -67.5% | 42% | – | – | – | |
| 同行中位数 | – | – | -32.4% | 0% | 9.1x | 6.8x | 18.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。